Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands
- PMID: 38597072
- DOI: 10.1111/vox.13633
Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands
Abstract
Background and objectives: Vaccine-induced thrombotic thrombocytopenia (VITT) is a rare adverse effect characterized by thrombocytopenia and thrombosis occurring after COVID-19 vaccination. VITT pathophysiology is not fully unravelled but shows similarities to heparin-induced thrombocytopenia (HIT). HIT is characterized by the presence of antibodies against platelet factor 4 (PF4)/heparin complex, which can activate platelets in an FcγRIIa-dependent manner, whereas IgG-antibodies directed against PF4 play an important role in VITT.
Materials and methods: We characterized all clinically suspected VITT cases in the Netherlands from a diagnostic perspective and hypothesized that patients who developed both thrombocytopenia and thrombosis display underlying mechanisms similar to those in HIT. We conducted an anti-PF4 ELISA and a functional PF4-induced platelet activation assay (PIPAA) with and without blocking the platelet-FcγRIIa and found positivity in both tests, suggesting VITT with mechanisms similar to those in VITT.
Results: We identified 65 patients with both thrombocytopenia and thrombosis among 275 clinically suspected VITT cases. Of these 65 patients, 14 (22%) tested positive for anti-PF4 and PF4-dependent platelet activation. The essential role of platelet-FcγRIIa in VITT with mechanisms similar to those in HIT was evident, as platelet activation was inhibited by an FcγRIIa-blocking antibody in all 14 patients.
Conclusion: Our study shows that only a small proportion of clinically suspected VITT patients with thrombocytopenia and thrombosis have anti-PF4-inducing, FcɣRIIa-dependent platelet activation, suggesting an HIT-like pathophysiology. This leaves the possibility for the presence of another type of pathophysiology ('non-HIT like') leading to VITT. More research on pathophysiology is warranted to improve the diagnostic algorithm and to identify novel therapeutic and preventive strategies.
Keywords: COVID‐19; platelet factor 4; thrombocytopenia; thrombosis; vaccination.
© 2024 International Society of Blood Transfusion.
Similar articles
-
Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):1-10. doi: 10.1182/hematology.2023000503. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066843 Free PMC article.
-
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia.Nature. 2021 Aug;596(7873):565-569. doi: 10.1038/s41586-021-03744-4. Epub 2021 Jul 7. Nature. 2021. PMID: 34233346
-
Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein.Blood. 2021 Oct 7;138(14):1269-1277. doi: 10.1182/blood.2021012938. Blood. 2021. PMID: 34280256 Free PMC article.
-
Therapeutic strategies in FcγIIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT).Expert Opin Pharmacother. 2024 Feb;25(3):281-294. doi: 10.1080/14656566.2024.2328241. Epub 2024 Mar 12. Expert Opin Pharmacother. 2024. PMID: 38465524 Review.
-
Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.Semin Thromb Hemost. 2023 Sep;49(6):621-633. doi: 10.1055/s-0042-1758818. Epub 2022 Dec 1. Semin Thromb Hemost. 2023. PMID: 36455619 Free PMC article. Review.
Cited by
-
The Ambivalence of Post COVID-19 Vaccination Responses in Humans.Biomolecules. 2024 Oct 17;14(10):1320. doi: 10.3390/biom14101320. Biomolecules. 2024. PMID: 39456253 Free PMC article. Review.
-
Endothelial cell activation enhances thromboinflammation in vaccine-induced immune thrombotic thrombocytopenia.Blood Adv. 2025 Jun 24;9(12):2891-2906. doi: 10.1182/bloodadvances.2024014165. Blood Adv. 2025. PMID: 40085945 Free PMC article.
References
REFERENCES
-
- Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV‐19 vaccination. N Engl J Med. 2021;384:2202–2211.
-
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov‐19 vaccination. N Engl J Med. 2021;384:2092–2101.
-
- Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund‐Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV‐19 vaccination. N Engl J Med. 2021;384:2124–2130.
-
- Muir K‐L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384:1964–1965.
-
- Figures on the COVID‐19 vaccination programme | RIVM. Available from: https://www.rivm.nl/en/covid-19-vaccination/figures-vaccination-programme. Last accessed 17 Jan 2023.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous